Literature DB >> 8807217

Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States.

R O Suara1, P A Piedra, W P Glezen, R A Adegbola, M Weber, E K Mulholland, B M Greenwood, H Whittle.   

Abstract

The prevalence of maternal respiratory syncytial virus (RSV)-neutralizing antibodies has been documented in developed countries, but there is little information from developing countries. We assessed the prevalence of RSV-neutralizing antibody in sera from Gambian women and their newborns and compared them with their American counterparts during a similar period. The geometric mean titers of maternal antibodies to RSV subgroup A in the two populations were similar, while titers of antibodies to RSV subgroup B in Gambian mothers were significantly higher (8.7 +/- 1.4 versus 7.9 +/- 1.3 [mean +/- standard deviation], P < 0.001). The titers of neutralizing antibody in newborns in both populations correlated with the neutralizing-antibody titers of their mothers. Thus, the status of neutralizing antibody to both major RSV subgroups was comparable among infants and mothers in a developing country, The Gambia, and those in a developed country, the United States.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807217      PMCID: PMC170373          DOI: 10.1128/cdli.3.4.477-479.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  18 in total

1.  Mortality from acute respiratory infections in children under 5 years of age: global estimates.

Authors:  J Leowski
Journal:  World Health Stat Q       Date:  1986

2.  Acute lower respiratory tract infection due to virus among hospitalized children in Dhaka, Bangladesh.

Authors:  F Huq; M Rahman; N Nahar; A Alam; M Haque; D A Sack; T Butler; R Haider
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus.

Authors:  C L Lamprecht; H E Krause; M A Mufson
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

4.  Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy.

Authors:  J B McCormick; H H Gusmão; S Nakamura; J B Freire; J Veras; G Gorman; J C Feeley; P Wingo
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

Review 5.  Epidemiology of acute respiratory infections in children of developing countries.

Authors:  S Berman
Journal:  Rev Infect Dis       Date:  1991 May-Jun

6.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

7.  Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.

Authors:  G A Prince; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

8.  Maternal antibody and respiratory syncytial virus infection in infancy.

Authors:  M M Ogilvie; A S Vathenen; M Radford; J Codd; S Key
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

9.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

Authors:  W P Glezen; A Paredes; J E Allison; L H Taber; A L Frank
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

10.  Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.

Authors:  P A Piedra; W P Glezen; J A Kasel; R C Welliver; A M Jewel; Y Rayford; D A Hogerman; S W Hildreth; P R Paradiso
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

View more
  16 in total

1.  Evaluation of IgG Antibodies Against Respiratory Syncytial Virus (RSV), and Associated Risk Factors for Severe Respiratory Tract Infections in Pre-School Children in North-Central, Nigeria.

Authors:  Adedayo Faneye; Babatunde O Motayo; Adeyinka Adesanmi; Bernard Onoja
Journal:  Afr J Infect Dis       Date:  2014

2.  Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh.

Authors:  Helen Y Chu; Mark C Steinhoff; Amalia Magaret; Khalequ Zaman; Eliza Roy; Gretchen Langdon; Mary Anne Formica; Edward E Walsh; Janet A Englund
Journal:  J Infect Dis       Date:  2014-06-05       Impact factor: 5.226

3.  Respiratory syncytial virus vaccine: Is it coming?

Authors:  Valérie Sales; Elaine El Wang
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

4.  Impact of Placental Malaria and Hypergammaglobulinemia on Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea.

Authors:  Jessica E Atwell; Bhagvanji Thumar; Leanne J Robinson; Roselyn Tobby; Phantica Yambo; Maria Ome-Kaius; Peter M Siba; Holger W Unger; Stephen J Rogerson; Christopher L King; Ruth A Karron
Journal:  J Infect Dis       Date:  2015-08-03       Impact factor: 5.226

Review 5.  Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.

Authors:  Jop Jans; Marloes Vissers; Jacco G M Heldens; Marien I de Jonge; Ofer Levy; Gerben Ferwerda
Journal:  Rev Med Virol       Date:  2013-11-14       Impact factor: 6.989

6.  Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.

Authors:  Cristina Capella; Supranee Chaiwatpongsakorn; Erin Gorrell; Zachary A Risch; Fang Ye; Sara E Mertz; Sara M Johnson; Melissa Moore-Clingenpeel; Octavio Ramilo; Asuncion Mejias; Mark E Peeples
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

7.  Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.

Authors:  Joyce U Nyiro; Charles Sande; Martin Mutunga; Patience K Kiyuka; Patrick K Munywoki; J Anthony G Scott; D James Nokes
Journal:  Vaccine       Date:  2015-02-26       Impact factor: 3.641

8.  Respiratory syncytial virus: a systematic scientometric analysis of the global publication output and the gender distribution of publishing authors.

Authors:  Dörthe Brüggmann; Corinna Köster; Doris Klingelhöfer; Jan Bauer; Daniela Ohlendorf; Matthias Bundschuh; David A Groneberg
Journal:  BMJ Open       Date:  2017-07-26       Impact factor: 2.692

9.  Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults.

Authors:  Louis Fries; Vivek Shinde; Jeffrey J Stoddard; D Nigel Thomas; Eloi Kpamegan; Hanxin Lu; Gale Smith; Somia P Hickman; Pedro Piedra; Gregory M Glenn
Journal:  Immun Ageing       Date:  2017-04-12       Impact factor: 6.400

10.  Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy.

Authors:  Helen Y Chu; Joanne Katz; James Tielsch; Subarna K Khatry; Laxman Shrestha; Steven C LeClerq; Amalia Magaret; Jane Kuypers; Mark C Steinhoff; Janet A Englund
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.